
Collegium Pharmaceutical (COLL) Stock Forecast & Price Target
Collegium Pharmaceutical (COLL) Analyst Ratings
Bulls say
Collegium Pharmaceutical Inc. is poised for strong growth, primarily driven by its successful product, Jornay PM, which has demonstrated a remarkable 19% year-over-year revenue increase, reaching $42 million, and capturing a market share of 23.4%. The company’s recent expansion of its sales force and focused digital marketing efforts are expected to bolster education and awareness among prescribers and patients, further supporting sales growth. Additionally, expected improvements in gross-to-net (GTN) ratios and a robust outlook for script growth in the adult segment position Collegium favorably for continued top-line performance in the upcoming years.
Bears say
Collegium Pharmaceutical Inc. faces significant risks that contribute to a negative outlook for its stock, primarily stemming from expected declines in sales from key products including Xtampza ER and the Nucynta franchise, as well as potential early generic competition for multiple offerings. The company's 2026 sales guidance reflects a decrease to approximately $620 million for its pain portfolio, indicating a slowdown from previous sales estimates. Additionally, risks surrounding commercialization, including supply chain issues and unfavorable reimbursement dynamics, could further hinder profitability and growth prospects.
This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Collegium Pharmaceutical (COLL) Analyst Forecast & Price Prediction
Start investing in Collegium Pharmaceutical (COLL)
Order type
Buy in
Order amount
Est. shares
0 shares